title: Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis.
abstract: OBJECTIVE
  To evaluate the efficacy of anti-tumour necrosis factor (anti-TNF) treatment in juvenile idiopathic arthritis (JIA)-associated uveitis.
  
  
  METHODS
  24 patients with uveitis taking etanercept and 21 taking infliximab were studied. The endpoint ophthalmological evaluation was at 24 months or at the termination of the first biological agent. The ocular inflammatory activity was graded on the basis of the number of anterior chamber cells.
  
  
  RESULTS
  Of the 45 patients, uveitis improved in 14 (31%), no change was observed in 14 (31%) and the activity of uveitis increased in 17 (38%). Inflammatory activity improved more frequently (p=0.047) in the patients taking infliximab than in those taking etanercept. The number of uveitis flares/year was higher (p=0.015) in the patients taking etanercept (mean 1.4, range 0-3.2) than in those taking infliximab (mean 0.7, range 0-2). Uveitis developed for the first time while taking anti-TNF treatment in five patients-4 taking etanercept (2.2/100 patient-years) and 1 taking infliximab (1.1/100 patient-years).
  
  
  CONCLUSIONS
  During anti-TNF treatment, the ophthalmological condition improved in one-third of the patients with uveitis. In chronic anterior uveitis, associated with refractory JIA, infliximab may be more effective than etanercept.
authors.affiliation: Department of Pediatric Rheumatology, Research Unit, Hospital for Children and Adolescents, Helinski University Central Hospital, 00029 HUS, Finland. pirjo.tynjala@hus.fi
authors.forename: Pirjo
authors.initials: P
authors.lastname: Tynjälä
authors.forename: Päivi
authors.initials: P
authors.lastname: Lindahl
authors.forename: Visa
authors.initials: V
authors.lastname: Honkanen
authors.forename: Pekka
authors.initials: P
authors.lastname: Lahdenne
authors.forename: Kaisu
authors.initials: K
authors.lastname: Kotaniemi
mesh_terms: D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001171:Arthritis, Juvenile / Q000150:complications* / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D004341:Drug Evaluation; D000068800:Etanercept; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use*; D007223:Infant; D000069285:Infliximab; D008297:Male; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014606:Uveitis, Anterior / Q000188:drug therapy* / Q000209:etiology
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept